Using mTOR Inhibitors to Treat Brain Tumors in Tuberous Sclerosis
Author Information
Author(s): Philippe Major
Primary Institution: Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal
Hypothesis
Can mTOR inhibitors serve as effective treatments for subependymal giant cell astrocytomas in patients with tuberous sclerosis complex?
Conclusion
mTOR inhibitors may provide a viable alternative to surgery for treating subependymal giant cell astrocytomas in tuberous sclerosis complex patients.
Supporting Evidence
- Everolimus treatment resulted in at least a 30% reduction in SEGA size in 75% of patients.
- SEGAs are benign tumors that can cause serious complications if left untreated.
- Long-term treatment with mTOR inhibitors may be necessary as SEGAs tend to regrow after treatment stops.
Takeaway
Doctors are looking at a special medicine that might help kids with a type of brain tumor called SEGA, which is linked to a condition called tuberous sclerosis.
Methodology
The study involved a phase II trial using everolimus to treat SEGAs in patients with TSC.
Limitations
The long-term side effects of mTOR inhibitors are still under investigation.
Participant Demographics
Patients with tuberous sclerosis complex, primarily in the pediatric age group.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website